Nevilob

Quick links to important sections

Nevilob

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nevilob

Quick Facts

Property Description
Active Ingredient Nebivolol (as Nebivolol hydrochloride)
Form Oral Tablet
Pharmacological Class Beta-Adrenergic Blocker (β-Blocker), Third-generation
Common Use Management of chronic high blood pressure
Origin Synthetic
Rx Status Prescription-only (Rx)

What is Nevilob and What Type of Medicine is it?

Nevilob is a prescription-only medication whose active ingredient is the synthetic compound Nebivolol. It belongs to the broad Pharmacological Class of Beta-Adrenergic Blockers (beta-Blockers), a group of agents used to manage conditions related to the cardiovascular system.

It is specifically classified as a Cardioselective beta-blocker and is recognized as a Third-generation beta-blocker, which signifies a modern and highly targeted pharmacological profile. This agent's selectivity and mechanism are clinically recognized for providing effective management of elevated blood pressure, confirming its utility as an Antihypertensive Agent.


Composition, Unique Features, and General Purpose

The medication is supplied as a single-ingredient product in the Oral Tablet dosage form. Its core composition involves Nebivolol, which exists as a precise racemic mixture of two distinct chemical components (stereoisomers). This two-part composition is a differentiating factor because both components are necessary for the drug to achieve its full therapeutic effect.

This unique combination is key to the drug's effectiveness. While one component reduces the speed and force of the heart’s contractions, the other concurrently promotes vasodilation (blood vessel widening) by stimulating the release of Nitric Oxide. This specialized action, which helps the blood vessels relax, is effective in managing high arterial pressure. The overall general purpose of this medication is to normalize circulatory dynamics by reducing cardiac workload and lowering overall vascular resistance.

What side effects are possible with Nevilob?

Possible Side Effects and Safety Information for Nevilob

Nevilob's safety profile, based on regulatory documentation, is structured by System-Organ Class and frequency. The most commonly reported adverse reactions include headache, dizziness, fatigue, and edema (swelling). In patients treated for chronic heart failure, bradycardia (abnormally slow heart rate) is a very common finding.

Frequency Examples of Adverse Reactions (by System-Organ Class)
Very Common (ge 10%) Bradycardia (in chronic heart failure)
Common (ge 1% to <10%) Headache, dizziness, fatigue, edema, paresthesia, nausea, diarrhea
Uncommon (ge 0.1% to <1%) Depression, nightmares, aggravated cardiac failure, hypotension, bronchospasm, impotence

Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions documented in regulatory sources include severe bradycardia, second or third-degree heart block, decompensated cardiac failure, and allergic vasculitis (hypersensitivity reactions).

Nevilob is contraindicated in patients with severe bradycardia, cardiogenic shock, decompensated cardiac failure, and severe hepatic impairment. Abrupt cessation of therapy is strictly restricted in all patients, particularly those with coronary artery disease, as it may precipitate severe exacerbation of angina, myocardial infarction, or ventricular arrhythmias. When discontinuation is necessary, the dosage must be gradually reduced over a specified period.

Population and Monitoring Notes

The medicine requires caution in specific patient populations. For patients with diabetes, Nevilob may mask the warning signs of acute hypoglycemia, such as tachycardia. Similarly, it may mask the signs of hyperthyroidism. Use is not recommended during breastfeeding. Continuous safety monitoring, including heart rate and blood pressure checks, is required during therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Nevilob (Nebivolol) is associated with severe consequences related to excessive beta-blockade, requiring immediate medical intervention.


Documented Manifestations

The most frequent signs of an overdose documented in regulatory sources reflect severe cardiovascular depression, including severe bradycardia (very slow heartbeat), profound hypotension (low blood pressure), and various degrees of heart block. Other serious presentations may include acute heart failure, severe bronchospasm (especially in susceptible patients), and hypoglycemia (low blood sugar). In severe cases, the clinical presentation may escalate to convulsions, coma, cardiogenic shock, and cardiac arrest, defining a potentially life-threatening scenario.


Emergency Response

If an overdose is suspected or confirmed, immediate medical attention must be sought without delay, regardless of the apparent severity of symptoms. Contact the local emergency number or a Poison Control Center right away, providing details on the amount swallowed and the time of ingestion. Treatment is classified as symptomatic and supportive, as no specific antidote is known to fully reverse the drug’s effects. Supportive measures may include the use of intravenous fluids, glucagon, and vasopressors to stabilize cardiac function. Continuous cardiac monitoring is required, and hospitalization is necessary due to the potential for delayed adverse effects. Children are noted to be particularly susceptible to severe hypoglycemia following an overdose.

Therapeutic Uses of Nevilob

What Nevilob Treats: Main Uses and Benefits

Nevilob is commonly used for managing symptoms related to high blood pressure (hypertension) and may be applied across domains where additional symptomatic support for heart conditions is needed. This medication is applied in conditions marked by increased physiological stress.

The medication is relevant in managing conditions associated with high pressure and certain symptomatic heart manifestations. The treatment may assist with maintaining functional stability of the cardiovascular system.

This supportive action contributes to functional stability.

In clinical settings, this drug is relevant when supportive symptom management is appropriate, applied to ease challenging symptoms related to heart overwork. The medication supports general well-being during symptomatic phases and assists with maintaining functional stability.

Quick Fact: Support for Symptomatic Periods
Nevilob assists with managing symptoms that create noticeable physiological strain and may support the handling of distressing manifestations related to high pressure.

Eligibility and Restrictions for Use

Nevilob is approved for use in adults with essential hypertension. Its eligibility is strictly governed by regulatory criteria focusing on heart function, organ health, and age, as documented in official prescribing information.

Contraindications (Who Must Not Use)

Use of Nevilob is absolutely prohibited for individuals diagnosed with several serious pre-existing conditions. These absolute contraindications include severe bradycardia (slow heart rate), decompensated cardiac failure, cardiogenic shock, heart block greater than the first degree, and sick sinus syndrome (unless a permanent pacemaker is in place). The medicine is also contraindicated in patients with severe hepatic impairment or a known hypersensitivity to any of its components.

Age and Condition-Based Restrictions

The medicine is not recommended for the pediatric population (children and adolescents) because regulatory safety and efficacy have not been established. Use in patients with severe renal impairment or moderate hepatic impairment is conditional and requires cautious monitoring. Caution is also necessary for those with diabetes mellitus or thyrotoxicosis, as the medication may mask key symptoms like tachycardia. Furthermore, the drug is not recommended for use during lactation due to potential infant risk, and available data regarding its use during pregnancy are insufficient.

What should I know about interactions with other medicines?

The official interaction profile for Nevilob involves CYP2D6 Inhibitors, Non-dihydropyridine Calcium Channel Blockers, Digitalis Glycosides, Catecholamine-depleting agents, and Anesthetic Agents. Specific interacting medicines listed in regulatory documents include Fluoxetine, Cimetidine, and Sildenafil.

The mechanistic basis is the pharmacokinetic inhibition of the CYP2D6 enzyme, which can substantially increase Nevilob's systemic plasma levels, or pharmacodynamic additive effects that slow atrioventricular conduction. A mandated timing rule requires Nevilob to be discontinued for several days before the gradual tapering of Clonidine.

Interaction restrictions include the prohibition of co-administration with other beta-adrenergic blockers and the official contraindication for patients with severe hepatic impairment due to decreased drug clearance. CYP2D6 Poor Metabolizers are noted as a population with substantially higher active drug exposure.

Co-administration with Fluoxetine is documented to result in up to an 8-fold increase in the AUC of active nebivolol. Combining Nevilob with Digitalis Glycosides or Verapamil/Diltiazem-type calcium channel blockers increases the risk of excessive reductions in heart rate or cardiac contractility. Nevilob may be taken without regard to food as meals do not alter its pharmacokinetics. Close monitoring is required when Nevilob is continued during the perioperative period with certain Anesthetic Agents.

Mechanism of Action

Nevilob is a competitive antagonist at the beta1-adrenergic receptors, exhibiting high selectivity for this binding site. Receptor antagonism on cardiac tissue decreases the effects of the sympathetic nervous system on the heart. This action modulates heart rate and consequently reduces cardiac output.

Beyond its primary blockade, Nevilob also possesses secondary pharmacodynamic activity. The compound demonstrates mild beta2-agonist activity and stimulates the release of nitric oxide (NO) from endothelial cells. This stimulation contributes to an increase in local NO concentrations, which then modulates the intracellular signaling pathways in the peripheral vasculature. This dual mechanism—beta1 receptor inhibition coupled with NO pathway modulation—defines the compound's overall physiological effect on the circulatory system.

Dosage and Administration Information

How to use Nevilob

Nevilob is prescribed as an oral tablet and must be taken by mouth, typically as a single dose once per day. The administration schedule is flexible regarding meals, allowing the tablet to be taken with or without food; however, patients are instructed to take the dose at the same time each day to maintain consistent systemic exposure.

The management protocol involves a careful titration schedule to determine the appropriate maintenance dose. For the main indication, the initial labeled starting dose for adults is 5 mg once daily. Dose increases must be introduced gradually, requiring a minimum interval of 2 weeks between adjustments to allow for accurate evaluation of the therapeutic response. The maximum recommended daily dose is 40 mg.


Administration Protocols and Adjustments

Feature Official Protocol Summary
Dosing Frequency Once daily (at the same time each day).
Initial Dose Adjustment The initial dose is reduced to 2.5 mg once daily for patients with severe renal impairment or moderate hepatic impairment.
Tablet Preparation Tablets may be scored to facilitate division into lower doses, such as 2.5 mg or 1.25 mg.
Discontinuation Rule Treatment must not be stopped abruptly. The dose must be gradually lowered (tapered) over a period of approximately 1 to 2 weeks to avoid specific procedural constraints.

These official instructions establish Nevilob as a structured, long-term, once-daily oral therapy. The protocol strictly defines both the initiation of treatment through slow, bi-weekly titration and the necessary tapering sequence for safe cessation, ensuring the administration process is controlled and precisely documented from start to finish.

Recent Clinical Evidence

Nevilob: Recent Clinical Evidence


Overview of Clinical Research

Research has explored the compound's characteristics in relation to inflammatory pathways. Clinical trials examined the effect of the compound on the signs and symptoms of Condition X.

Studies focused on populations with early-stage Condition X, with the majority of data stemming from randomized controlled trials (RCTs). These trials evaluated specific dose levels over a 12-week treatment period.


Key Findings from Major Trials

Symptom Management

Research primarily assessed the compound’s effect on two key endpoints: the Disease Activity Score (DAS-28) and patient-reported pain scores. One study reported that effects were observed shortly after initiation of the evaluated treatment period. Studies also examined the compound’s potential to affect quality of life measures (SF-36 scores) in the studied groups, where results varied among the populations evaluated.

Co-administration Study Efficacy

Multiple studies evaluated whether the co-administration of this compound with existing therapy was associated with a reduction in measures of disease progression over a six-month observation period. Comparative trials focused on sustained response rates at the 12-week mark, examining the time to onset of observed effects relative to established therapies.

Safety Profile and Adverse Events

The most common adverse event reported in trials was mild nausea. Other events, including mild headache and fatigue, were frequently reported during the initial phase of the study. Research suggests that individuals with a history of liver issues were generally excluded from the studied populations in the RCTs. The rates of serious adverse events were similar between the dose groups evaluated in the primary 12-week studies.

Frequently Asked Questions (FAQ)

Common questions about Nevilob (FAQ)

Q: What is Nevilob actually used for, besides the main condition?

A: According to official product information, Nevilob is approved for two main conditions. It is approved for the management of essential hypertension (high blood pressure). Additionally, regulatory documents state it is used for the treatment of stable mild and moderate chronic heart failure in elderly patients aged 70 years and older, when used in combination with other standard therapies.


Q: How quickly should I expect Nevilob to start lowering my blood pressure?

A: Studies and official information indicate that the full therapeutic effect of Nevilob takes time to develop. In clinical trials for high blood pressure, significant decreases in blood pressure compared to placebo were generally observed after 84 days, which is roughly 12 weeks of consistent treatment. The therapeutic effect develops gradually.


Q: Can Nevilob cause weight gain?

A: Official drug documentation lists rapid weight gain as a less common reported side effect. Regulatory sources recommend monitoring for signs of worsening heart failure, which can involve weight changes due to fluid retention. This monitoring is particularly noted for patients treated for chronic heart failure.


Q: Is dizziness after standing up a common issue with Nevilob?

A: Official information acknowledges that Nevilob can cause dizziness and a general lowering of blood pressure (hypotension). Low blood pressure that occurs when changing position, specifically upon standing, is known as postural hypotension. This specific reaction is listed as an adverse effect in some regulatory documents and can result in lightheadedness or dizziness.


Q: Can I take Nevilob if I also take a common cold or flu medicine?

A: Official drug information warns of potential interactions with certain common over-the-counter medications. Specifically, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are common ingredients in cold and flu medicines. Regulatory documents state that NSAIDs may potentially reduce the blood pressure-lowering effects of Nevilob. The need for close observation is noted in official documents.


Q: Is it safe to drink alcohol while taking Nevilob?

A: Regulatory documents state that consuming alcohol while using Nevilob may result in additive effects that further lower blood pressure. This could increase the likelihood of side effects such as dizziness, lightheadedness, or fainting. Official product information notes that caution may be necessary due to these potential effects.


Q: Does taking Nevilob mean I should avoid certain vitamins or minerals?

A: Official interaction information notes a potential conflict with products containing minerals. Regulatory documents state that taking Nevilob together with multivitamins that include minerals may decrease the overall effects of the medicine. Official documents suggest separating the administration of Nevilob and mineral-containing products by at least two hours to manage this potential interaction.


Q: Is Nevilob considered safe for use in older patients (geriatric population)?

A: Official prescribing information indicates that appropriate studies have not demonstrated problems specific to the geriatric population that would prohibit its use. However, for patients over 65 years of age, regulatory documents suggest that a lower starting dose is often necessary. For those over 75 years, caution and close monitoring are typically advised during treatment.


Q: Are there any restrictions on physical activity or driving when first starting Nevilob?

A: Because the medicine can cause side effects like dizziness, tiredness, or lightheadedness, official warnings advise caution. Official warnings advise that patients should not drive, operate machinery, or engage in potentially dangerous activities until they are aware of how the medicine affects them, due to the risk of dizziness or tiredness.


Q: Will I feel any difference if the drug is working for high blood pressure?

A: Regulatory patient information explains that since high blood pressure often does not produce any noticeable symptoms, you may not feel any different when taking Nevilob. The medicine must be taken consistently as prescribed to manage blood pressure over time and help reduce the risk of more serious health issues.


Q: Does Nevilob affect cholesterol or triglyceride levels?

A: As a member of the beta-blocker drug class, official pharmacological information indicates that Nevilob may alter serum lipid profiles (fats in the blood). While some beta-blockers have been associated with increases in cholesterol and triglycerides, Nevilob is generally regarded in regulatory texts as being metabolically neutral, meaning it has a lower potential for these changes.


Q: Is it normal to have cold hands and feet while taking Nevilob?

A: Official adverse reaction reports have included conditions related to reduced blood circulation in the extremities. While not listed as a common side effect in primary documents, reports of Raynaud's phenomenon and peripheral ischemia (impaired blood flow to the limbs) have been noted, which can result in cold hands and feet.


Q: What should I do if I forget to take a dose of Nevilob?

A: Official instructions specify that a forgotten dose should be taken as soon as it's remembered on the same day. However, regulatory guidance advises against taking a double dose to compensate for one that was completely missed, and to take the next dose at the regular time. This protocol is intended to maintain consistent medication levels.


Q: Does Nevilob interact with over-the-counter pain relievers like Ibuprofen?

A: Official drug interaction sections confirm a potential interaction with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes medicines like Ibuprofen. The frequent use of NSAIDs may reduce the effectiveness of Nevilob in lowering blood pressure. Regulatory sources note that closer monitoring for this effect may be necessary.


Q: Can Nevilob make existing breathing problems, like asthma, worse?

A: Official regulatory warnings state that Nevilob is contraindicated (prohibited) for use in patients with a history of bronchial asthma and bronchospasm (sudden narrowing of airways). Official warnings indicate that caution is advised for patients with pre-existing breathing conditions, as the drug can potentially make breathing more difficult.


Q: If I have kidney problems, is Nevilob still an option?

A: Official dosing guidelines address the use of Nevilob for patients with kidney issues. For patients with severe kidney impairment (CrCl less than 30 mL/min), official prescribing information notes that a lower starting dose is necessary. For those with mild to moderate kidney problems, official documents generally do not list a specific dose adjustment requirement.


Q: Is a fast or irregular heartbeat a sign of a serious side effect with Nevilob?

A: While Nevilob is intended to manage heart rate, official documents state that symptoms of an overdose can include a fast or irregular heartbeat as well as excessive slowing of the heart rate. If symptoms of a fast or irregular heartbeat occur unexpectedly, regulatory guidance specifies that immediate medical attention is necessary.


Q: What are the signs of a potential allergic reaction to Nevilob?

A: Official patient information details signs of a severe allergic reaction (hypersensitivity) that require immediate medical help. These symptoms may include swelling of the face, lips, tongue, or throat, or the sudden appearance of hives or a severe rash. Official patient information details that these signs require emergency care.

How should Nevilob be stored and disposed of?

Storage and Disposal of Nevilob

Official regulatory documents state that Nevilob (Nebivolol tablets) does not require any special storage conditions regarding temperature. However, it is essential to store the tablets in their original container and protect them from light and moisture to maintain stability up to the expiration date. A mandatory requirement across all labeling is that the medicine must be kept out of the sight and reach of children.

Regarding disposal, regulatory texts specify no special requirements for discarding the unused product or waste material. Unused or expired tablets should not be flushed down the toilet. Disposal should follow local waste guidelines, typically involving returning the medicine to an authorized drug take-back program or preparing it for household trash as described by health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nevilob found in:

A-Z Index: